HLB Group announced on March 10 that Chairman Jin Yang-gon purchased 71,000 shares of HLB Panagene, 38,000 shares of HLB Innovation, and 33,000 shares of HLB Therapeutics on the open market on March 4.


HLB Group Chairman Jin Yang-gon Purchases Affiliate Shares... "Responsible Management, Confidence in Growth" View original image

The purchases were made amid a sharp decline in the domestic stock market, as the KOSPI dropped by 12.06% and the KOSDAQ by 14% on the same day, following the outbreak of war between the United States and Iran and heightened geopolitical tensions. This move is seen as a demonstration of responsible management and a renewed show of confidence in the corporate value of the group’s subsidiaries.


Earlier this year, Chairman Jin purchased 160,000 shares of HLB Innovation in two transactions and 299,811 shares of HLB Panagene in eight transactions, signaling his strong belief in the company’s growth potential to the market.


It is noteworthy that all three companies in which Chairman Jin has increased his stake are approaching significant events related to new drug development. HLB Innovation plans to announce interim clinical results of its solid tumor CAR-T therapy at the American Association for Cancer Research (AACR) next month, while HLB Therapeutics is expected to release topline results in June from the global Phase 3 clinical trial of its subsidiary Regentree’s treatment for neurotrophic keratitis (NK).


HLB Panagene is working to establish a new growth pillar as a platform company by developing next-generation platform antibody-oligonucleotide conjugate (AOC) therapeutics that overcome the limitations of antibody-drug conjugates (ADC).


An HLB Group representative stated, "External factors such as war are difficult to predict or control, but expectations for the technological capabilities and business performance that our subsidiaries have accumulated are much more measurable. For this reason, the share purchases were made as an expression of responsible management and confidence in corporate value."



Meanwhile, the market has also taken note of BlackRock, the world's largest asset manager, publicly announcing that it has acquired more than 5% of HLB’s shares. This is the first time that BlackRock has disclosed an acquisition of more than 5% in a domestic bio company.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing